These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 29067667)

  • 41. Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup.
    Matsumoto M; Awano H; Lee T; Takeshima Y; Matsuo M; Iijima K
    Neuromuscul Disord; 2017 Nov; 27(11):1023-1028. PubMed ID: 28734761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation.
    Gussoni E; Bennett RR; Muskiewicz KR; Meyerrose T; Nolta JA; Gilgoff I; Stein J; Chan YM; Lidov HG; Bönnemann CG; Von Moers A; Morris GE; Den Dunnen JT; Chamberlain JS; Kunkel LM; Weinberg K
    J Clin Invest; 2002 Sep; 110(6):807-14. PubMed ID: 12235112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human multipotent adipose-derived stem cells restore dystrophin expression of Duchenne skeletal-muscle cells in vitro.
    Vieira NM; Brandalise V; Zucconi E; Jazedje T; Secco M; Nunes VA; Strauss BE; Vainzof M; Zatz M
    Biol Cell; 2008 Apr; 100(4):231-41. PubMed ID: 17997718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Kidney involvement and associated risk factors in children with Duchenne muscular dystrophy.
    Kutluk MG; Doğan ÇS
    Pediatr Nephrol; 2020 Oct; 35(10):1953-1958. PubMed ID: 32447503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
    Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
    Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy.
    Guo C; Willem M; Werner A; Raivich G; Emerson M; Neyses L; Mayer U
    Hum Mol Genet; 2006 Mar; 15(6):989-98. PubMed ID: 16476707
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amelioration of muscular dystrophy by transgenic expression of Niemann-Pick C1.
    Steen MS; Adams ME; Tesch Y; Froehner SC
    Mol Biol Cell; 2009 Jan; 20(1):146-52. PubMed ID: 18946078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DMD and West syndrome.
    Cardas R; Iliescu C; Butoianu N; Seferian A; Gataullina S; Gargaun E; Nectoux J; Bienvenu T; Craiu D; Gidaro T; Servais L
    Neuromuscul Disord; 2017 Oct; 27(10):911-913. PubMed ID: 28802771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
    Miura P; Jasmin BJ
    Trends Mol Med; 2006 Mar; 12(3):122-9. PubMed ID: 16443393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic and Early Clinical Manifestations of Females Heterozygous for Duchenne/Becker Muscular Dystrophy.
    Papa R; Madia F; Bartolomeo D; Trucco F; Pedemonte M; Traverso M; Broda P; Bruno C; Zara F; Minetti C; Fiorillo C
    Pediatr Neurol; 2016 Feb; 55():58-63. PubMed ID: 26718981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutation spectrum analysis of Duchenne/Becker muscular dystrophy in 68 families in Kuwait: The era of personalized medicine.
    Mohammed F; Elshafey A; Al-Balool H; Alaboud H; Al Ben Ali M; Baqer A; Bastaki L
    PLoS One; 2018; 13(5):e0197205. PubMed ID: 29847600
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection.
    Anaya-Segura MA; García-Martínez FA; Montes-Almanza LA; Díaz BG; Avila-Ramírez G; Alvarez-Maya I; Coral-Vazquez RM; Mondragón-Terán P; Escobar-Cedillo RE; García-Calderón N; Vazquez-Cardenas NA; García S; López-Hernandez LB
    Molecules; 2015 Jun; 20(6):11154-72. PubMed ID: 26091074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of dystrophin mRNA from skeletal muscle but not from lymphocytes led to identification of a novel nonsense mutation in a carrier of Duchenne muscular dystrophy.
    Ito T; Takeshima Y; Yagi M; Kamei S; Wada H; Nakamura H; Matsuo M
    J Neurol; 2003 May; 250(5):581-7. PubMed ID: 12736738
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle.
    Farini A; Sitzia C; Cassinelli L; Colleoni F; Parolini D; Giovanella U; Maciotta S; Colombo A; Meregalli M; Torrente Y
    Development; 2016 Feb; 143(4):658-69. PubMed ID: 26884398
    [TBL] [Abstract][Full Text] [Related]  

  • 55. COUP-TFII regulates satellite cell function and muscular dystrophy.
    Xie X; Tsai SY; Tsai MJ
    J Clin Invest; 2016 Oct; 126(10):3929-3941. PubMed ID: 27617862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox pathway.
    Petrillo S; Pelosi L; Piemonte F; Travaglini L; Forcina L; Catteruccia M; Petrini S; Verardo M; D'Amico A; Musarò A; Bertini E
    Hum Mol Genet; 2017 Jul; 26(14):2781-2790. PubMed ID: 28472288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The muscle regeneration marker FOXP3 is associated with muscle injury in Duchenne muscular dystrophy.
    Yannin Hernández-de la Cruz S; Ordaz-Robles T; Antonio Villaldama-Soriano M; Emmanuel Luna-Guzmán C; Almeida-Becerril T; Villa-Morales J; Cárdenas-Conejo A; Dolores Ruíz-Cruz E; Maldonado-Hernandez J; Bernabe-Garcia M; Barbosa-Cortés L; Rodríguez-Cruz M
    Brain Dev; 2024 May; 46(5):199-206. PubMed ID: 38388302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Duchenne Muscular Dystrophy Myogenic Cells from Urine-Derived Stem Cells Recapitulate the Dystrophin Genotype and Phenotype.
    Falzarano MS; D'Amario D; Siracusano A; Massetti M; Amodeo A; La Neve F; Maroni CR; Mercuri E; Osman H; Scotton C; Armaroli A; Rossi R; Selvatici R; Crea F; Ferlini A
    Hum Gene Ther; 2016 Oct; 27(10):772-783. PubMed ID: 27530229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
    Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
    Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
    Niezgoda A; Biegański G; Wachowiak J; Czarnota J; Siemionow K; Heydemann A; Ziemiecka A; Sikorska MH; Bożyk K; Siemionow M
    Arch Immunol Ther Exp (Warsz); 2023 Nov; 71(1):24. PubMed ID: 37999748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.